CompletedEarly Phase 1

Carboprost (Hemabate) for Fibroid Resection

United States19 participantsStarted 2022-07-12

Plain-language summary

The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients scheduled to undergo myomectomy with a surgeon in the division of Minimally Invasive Gynecologic Surgery * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * If any oxytocic agents have been or will be administered prior to surgery * History of renal and/or hepatic impairment * Active cardiac disease, pulmonary disease, or pelvic inflammatory disease (PID) * Anemia (Hgb \< 7g/dL), diabetes mellitus, jaundice, or epilepsy

What they're measuring

Does instillation of low-dose carboprost facilitate complete resection of FIGO II fibroids during hysteroscopic resection?

Timeframe: Pre-operatively to 1 month post-operatively

Trial details

NCT IDNCT05518812

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-06

View on ClinicalTrials.gov More Fibroid Uterus trials